Alloreactive CD8+ T cell (None)

Alloreactive CD8+ T cells are cytotoxic T lymphocytes that recognize and respond to foreign (allogeneic) major histocompatibility complex (MHC) class I molecules on transplanted tissues. These cells play a central role in transplant rejection by directly attacking nonmalignant host or graft tissues through MHC class I-restricted mechanisms. Upon encountering allogeneic antigens, these cells undergo proliferation and differentiation, transitioning through various phenotypic stages characterized by markers such as CD45RA, CD45RO, CD27, and acquiring effector functions including cytokine production and cytotoxic capabilities. They employ multiple mechanisms to eliminate target cells, including perforin/granzyme B-mediated cytotoxicity and Fas/FasL death pathways. Recent research has identified distinct subsets including TCF1+ progenitor cells that maintain proliferative capacity and can differentiate into TCF1- effector cells. The differentiation and expansion of alloreactive CD8+ T cells is closely linked to the number of cell divisions they undergo, with highly proliferated cells acquiring enhanced effector functions such as IFN-γ production. While these cells are essential mediators of transplant rejection, understanding their biology has implications for developing immunotherapeutic strategies to promote transplant tolerance and prevent graft-versus-host disease.

Other names

Alloreactive cytotoxic T cellsAlloreactive CD8+ T lymphocytesAllo-specific CD8+ T cellsKiller T cells (in alloimmune context)

These cells recognize mismatched MHC class I molecules on transplanted tissues through their T cell receptors and initiate direct cytotoxic responses. They differentiate through various stages marked by CD45RA/RO expression, CD27, and other surface markers, producing effector functions including direct killing and cytokine secretion.